Literature DB >> 7544900

Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons.

M J Benvenga1, J D Leander.   

Abstract

The effects of olanzapine [LY 170053; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2, 3b] [1,5]benzodiazepine), a potential atypical antipsychotic, were determined in pigeons whose keypeck responding was punished. These effects were compared to the anxiolytic agents chlordiazepoxide and pentobarbital, and to other antipsychotic agents. Keypeck behavior was maintained under a multiple FR30 FR30 schedule, signalled by white and red stimulus lights, respectively. Each component of the schedule alternated every 3 min with a 30-s timeout. During the white keylight component, responding was maintained by food presentation. During the red keylight component, responding was maintained by food and simultaneously suppressed by electric shock presentation, with response rates being only about 5% of those during the white stimulus light. Olanzapine (0.01-1.0 mg/kg) increased punished responding at doses below those which had an effect on unpunished responding. Clozapine (0.01-1.0 mg/kg), ritanserin (0.1-3.0 mg/kg), and, to a lesser extent, risperidone (0.1-1.0 mg/kg) were also effective at increasing punished responding. Generally, the maximum effect seen with olanzapine was equal to that seen with ritanserin, and it exceeded that seen with clozapine. However, these effects were generally less than those seen with chlordiazepoxide and pentobarbital. Haloperidol (0.01-0.1 mg/kg) was completely without effect on punished responding, while it caused decreases in unpunished behavior. These results provide further evidence that olanzapine has a profile in behavioral tests unlike the typical antipsychotic haloperidol. Moreover, this profile is similar to clozapine, a clinically effective antipsychotic with an atypical profile.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7544900     DOI: 10.1007/bf02246153

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  A technique for delivering shock to pigeons.

Authors:  N H AZRIN
Journal:  J Exp Anal Behav       Date:  1959-04       Impact factor: 2.468

2.  The history of clozapine.

Authors:  H Hippius
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 3.  Behavioral pharmacology of antagonists at 5-HT2/5-HT1C receptors.

Authors:  W Koek; A Jackson; F C Colpaert
Journal:  Neurosci Biobehav Rev       Date:  1992       Impact factor: 8.989

Review 4.  Biochemical and behavioural properties of clozapine.

Authors:  D M Coward; A Imperato; S Urwyler; T G White
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

6.  Effects of four antipsychotics on punished responding in rats.

Authors:  J L Wiley; A D Compton; J H Porter
Journal:  Pharmacol Biochem Behav       Date:  1993-06       Impact factor: 3.533

7.  The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.

Authors:  N A Moore; N C Tye; M S Axton; F C Risius
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

Review 8.  New anxiolytics in development.

Authors:  M Mosconi; C Chiamulera; G Recchia
Journal:  Int J Clin Pharmacol Res       Date:  1993

9.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.

Authors:  P A Janssen; C J Niemegeers; F Awouters; K H Schellekens; A A Megens; T F Meert
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

10.  Flumezapine, an antagonist of central dopamine and serotonin receptors.

Authors:  R W Fuller; N R Mason
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1986-10
View more
  6 in total

1.  Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

Authors:  F P Bymaster; S K Hemrick-Luecke; K W Perry; R W Fuller
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

Authors:  M E Stockton; K Rasmussen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 4.  Olanzapine: an updated review of its use in the management of schizophrenia.

Authors:  N Bhana; R H Foster; R Olney; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.

Authors:  B Fulton; K L Goa
Journal:  Drugs       Date:  1997-02       Impact factor: 9.546

Review 6.  Olanzapine: a review of its use in the treatment of bipolar I disorder.

Authors:  N Bhana; C M Perry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.